Results 41 to 50 of about 21,338 (215)
Pharmaceuticals, 2023 The approval of different cytokines as anti-neoplastic agents has been challenged by dose-limiting toxicities. Although reducing dose levels affords improved tolerability, efficacy is precluded at these suboptimal doses.
Nikolas T. Martin +17 more
doaj +1 more source
Advanced Science, EarlyView.To maximize the efficacy of cancer vaccines, adjuvants, collection, lysis, purification, oxidation, loading sites, and sizes, etc., are investigated. The optimized cancer nanovaccines loading whole tumor antigens can cure all or most tumor‐bearing mice in multiple mouse cancer models.
Xiangxiang Xu +13 more
wiley +1 more source
ODE models for oncolytic virus dynamics [PDF]
Journal of Theoretical Biology, 2010 Replicating oncolytic viruses are able to infect and lyse cancer cells and spread through the tumor, while leaving normal cells largely unharmed. This makes them potentially useful in cancer therapy, and a variety of viruses have shown promising results in clinical trials.
Dominik Wodarz, Natalia L. Komarova
openaire +3 more sources
Communications Biology, 2022 A secondary (but not primary) dose of the oncolytic virus, VSV, is captured by monocytes and promotes CD8 + T cell recruitment, thereby revealing a mechanism underlying the clinical benefit of repeat dosing in oncolytic virus therapy.
Victor Naumenko +14 more
doaj +1 more source
Recent Advances in mRNA Delivery Systems for Cancer Therapy
Advanced Science, EarlyView.This review systematically investigates the applications of mRNA therapy in cancer treatment, with particular emphasis on nonviral delivery systems, targeting strategies, stimulus‐responsive systems, and local delivery methods. Concluding with a meticulous evaluation, the review sheds light on the prevailing challenges while illuminating promising ...
Zheng Zhang +9 more
wiley +1 more source
Advances in Oncolytic Virus Therapy for Glioma [PDF]
Recent Patents on CNS Drug Discovery, 2009 The World Health Organization grossly classifies the various types of astrocytomas using a grade system with grade IV gliomas having the worst prognosis. Oncolytic virus therapy is a novel treatment option for GBM patients. Several patents describe various oncolytic viruses used in preclinical and clinical trials to evaluate safety and efficacy.
Abhik Ray Chaudhury +3 more
openaire +3 more sources
Advanced Science, EarlyView.This review compares clinical outcomes, translational progress, and global funding trends across cancer phototherapies—photodynamic, photothermal, and photoimmunotherapy—and conventional immunotherapy. It highlights differences in treatment efficacy, clinical trial status, financial investment, and regulatory challenges, providing a comprehensive ...
Deepak S. Chauhan +6 more
wiley +1 more source
Advanced Science, EarlyView.ICAM1 antibody‐bound ICG triggers tumor‐specific, caspase‐1‐independent pyroptosis via CTSS‐mediated GSDMD cleavage, activates antitumor immunity, and synergizes with anti–PD‐1 therapy, offering a non‐apoptotic strategy to overcome resistance in cancer treatment.
Fan Chen +17 more
wiley +1 more source
Suppression of CCDC6 sensitizes tumor to oncolytic virus M1
Neoplasia: An International Journal for Oncology Research, 2021 Oncolytic virus is an effective therapeutic strategy for cancer treatment, which exploits natural or manipulated viruses to selectively target and kill cancer cells.
Ying Liu +12 more
doaj
Journal for ImmunoTherapy of Cancer, 2018 Antiviral responses are barriers that must be overcome for efficacy of oncolytic virotherapy. In mammalian cells, antiviral responses involve the interferon pathway, a protein-signaling cascade that alerts the immune system and limits virus propagation ...
Donald Bastin +8 more
doaj +1 more source